Avenzo Therapeutics, founded by Athena Countouriotis and Mohammad Hirmand, seasoned veterans in the life science industry, is making waves in the field of oncology. Following Countouriotis' successful tenure as CEO of Turning Point Therapeutics, which was acquired by Bristol Myers Squibb for $4.1 billion, the duo embarked on a new venture to address unmet needs in cancer treatment. Avenzo Therapeutics, focuses on developing innovative solutions for hard-to-treat tumors, with a lead drug targeting resistance pathways in metastatic breast cancer and solid tumors.
Avenzo’s recent success in exceeding its initial fundraising goal underscores the confidence investors have in the company's vision and expertise. With a $150 million Series A round led by prominent investors like New Enterprise Associates and Sofinnova Investments, Avenzo is well-positioned to advance its lead drug through clinical trials and expand its pipeline to include treatments for other challenging cancers such as ovarian. Countouriotis emphasizes the potential of their lead drug to offer a more potent and selective approach, potentially minimizing side effects while addressing the pressing needs of patients who have exhausted current treatment options. As Avenzo continues to grow, its efforts hold promise for transforming cancer care and improving outcomes for patients worldwide.
